ImmunoTherapeutics Inc. entered into a letter of intent to license itsdeveloped by Jenner Technologies of Danville, Calif.Gerald Vosika, ImmunoTherapeutics' president and scientific director,told BioWorld the agreement would call for milestone payments androyalties. Further terms were not revealed.ImmunoTherapeutics of Fargo, N.D., has focused on the application ofimmunostimulants to the treatment of cancer. It has one drug,ImmTher, in Phase II clinical trials for metastatic colorectal cancer,prostate cancer and malignant melanoma. A second drug, Theramide, isin Phase I trials for patients with advanced cancer who failedchemotherapy.Jenner is focusing on recombinant-based vaccines and the use ofadjuvants and carrier systems to enhance the number and activity ofcytotoxic T-lymphocytes to combat cancer cells after surgery. _ JimShrine

(c) 1997 American Health Consultants. All rights reserved.